Johnson & Johnson Talc Settlement: $5.5 Billion Deal Ends Cancer Suits

The Johnson & Johnson talc settlement is finally here, and it comes with a number large enough to make headlines on its own. Johnson & Johnson said on Monday that it will pay $5.5 billion to resolve close to 70,000 lawsuits claiming its baby powder and other talc-based products caused ovarian cancer, closing out one of the longest-running product liability battles in American corporate history.

The company confirmed the deal covers roughly 69,000 cases consolidated in federal court in New Jersey, along with related state court claims, together accounting for 99.75 percent of the talc lawsuits still outstanding. Plaintiffs’ law firms signed off on the agreement the same day, calling it a fair outcome after ten years of legal trench warfare.

There is a catch worth flagging. The settlement is not automatically final. It needs sign-off from participating law firms representing at least 95 per cent of the claims, and a judge overseeing the federal litigation must still approve it. So this is a major milestone, not quite the last word.

A decade of denial and delay

J&J has never budged on the science. The company insists its talc was safe, that it never contained asbestos, and that the cancer claims tied to its products are without merit. Erik Haas, J&J’s vice president of litigation, described the underlying claims as meritless even as he confirmed the company’s willingness to settle, framing the payout as a way to buy closure rather than an admission of fault.

That posture held even after the company pulled talc-based Johnson’s Baby Powder off shelves in the United States in 2020, switching to a cornstarch formula, and later withdrew the talc version from markets worldwide in 2023. Removing the product did not remove the lawsuits, which kept multiplying as juries across the country weighed in.

The road here was anything but smooth. J&J tried three separate times to push the talc claims into bankruptcy through a subsidiary, a strategy critics branded the “Texas two step.” Courts rejected each attempt, and in March 2025 a bankruptcy judge shot down the company’s third plan outright. J&J chose not to appeal, which forced the fight back into ordinary courtrooms and effectively ended the bankruptcy detour.

Juries did not go easy on the company once the cases resumed. A California jury ordered J&J last October to pay nearly a billion dollars to the family of a woman who blamed her cancer on decades of using the baby powder, the largest single user verdict in the litigation’s history. A Florida jury separately awarded $20 million in a related mesothelioma case the same month.

Why J&J blinked now

Analysts had been warning that the financial exposure was only growing. Bloomberg Intelligence estimated before the deal that J&J could have faced costs of $10 billion to $12 billion had roughly 93,000 individual suits gone to trial. Weigh that number against a $5.5 billion settlement, and the arithmetic behind Monday’s announcement becomes easier to follow.

Timing mattered too. Just last week, a federal judge raised doubts about whether individual plaintiffs could prove that talc specifically, rather than some other factor, caused their ovarian cancer. This ruling strengthened J&J’s hand at the negotiating table even as it agreed to pay up.

Markets reacted calmly. J&J shares rose about 1 percent in after-hours trading following the news, suggesting investors read the settlement as a relief rather than a shock, the cost of finally shutting the door on litigation that had shadowed the company for fifteen years.

What this does not settle

Unlike the earlier bankruptcy proposals, this agreement covers only existing claims. It does not address future lawsuits, meaning talc litigation against J&J could resurface if new plaintiffs come forward. And the company still faces separate legal exposure abroad, including an ongoing case in the United Kingdom.

For now, though, the J&J talc settlement marks the closest the company has come to turning the page on a legal saga that outlasted three attempted bankruptcies, dozens of trials and a decade of headlines that refused to fade.